Protéomique et cancer du sein : à la recherche de nouveaux biomarqueurs diagnostiques et théragnostiques
Tóm tắt
Từ khóa
Tài liệu tham khảo
Anderson, 1997, A comparison of selected mRNA and protein abundances in human liver, Electrophoresis, 18, 533, 10.1002/elps.1150180333
Chen, 2003, Protein profiles associated with survival in lung adenocarcinoma, Proc Natl Acad Sci U S A, 100, 13537, 10.1073/pnas.2233850100
Ginestier, 2002, Distinct and complementary information provided by use of tissue and DNA microarrays in the study of breast tumor markers, Am J Pathol, 161, 1223, 10.1016/S0002-9440(10)64399-4
Gygi, 1999, Correlation between protein and mRNA abundance in yeast, Mol Cell Biol, 19, 1720, 10.1128/MCB.19.3.1720
Battifora, 1986, The multitumor (sausage) tissue block: novel method for immunohistochemical antibody testing, Lab Invest, 55, 244
Wan, 1987, A rapid and efficient method for testing immunohistochemical reactivity of monoclonal antibodies against multiple tissue samples simultaneously, J Immunol Methods, 103, 121, 10.1016/0022-1759(87)90249-3
Camp, 2008, A decade of tissue microarrays: progress in the discovery and validation of cancer biomarkers, J Clin Oncol, 26, 5630, 10.1200/JCO.2008.17.3567
Hoos, 2001, Tissue microarray profiling of cancer specimens and cell lines: opportunities and limitations, Lab Invest, 81, 1331, 10.1038/labinvest.3780347
Bubendorf, 1999, Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays, J Natl Cancer Inst, 91, 1758, 10.1093/jnci/91.20.1758
Torhorst, 2001, Tissue microarrays for rapid linking of molecular changes to clinical endpoints, Am J Pathol, 159, 2249, 10.1016/S0002-9440(10)63075-1
Kononen, 1998, Tissue microarrays for high-throughput molecular profiling of tumor specimens, Nat Med, 4, 844, 10.1038/nm0798-844
Camp, 2002, Automated subcellular localization and quantification of protein expression in tissue microarrays, Nat Med, 8, 1323, 10.1038/nm791
Camp, 2003, Quantitative analysis of breast cancer tissue microarrays shows that both high and normal levels of HER2 expression are associated with poor outcome, Cancer Res, 63, 1445
Harigopal, 2005, Automated quantitative analysis of E-cadherin expression in lymph node metastases is predictive of survival in invasive ductal breast cancer, Clin Cancer Res, 11, 4083, 10.1158/1078-0432.CCR-04-2191
Rubin, 2004, Quantitative determination of expression of the prostate cancer protein alpha-methylacyl-CoA racemase using automated quantitative analysis (AQUA): a novel paradigm for automated and continuous biomarker measurements, Am J Pathol, 164, 831, 10.1016/S0002-9440(10)63171-9
Giltnane, 2004, Technology insight: Identification of biomarkers with tissue microarray technology, Nat Clin Pract Oncol, 1, 104, 10.1038/ncponc0046
Hedenfalk, 2001, Gene-expression profiles in hereditary breast cancer, N Engl J Med, 344, 539, 10.1056/NEJM200102223440801
Palacios, 2005, Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers, Breast Cancer Res Treat, 90, 5, 10.1007/s10549-004-1536-0
Bane, 2007, BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays, Am J Surg Pathol, 31, 121, 10.1097/01.pas.0000213351.49767.0f
Jacquemier, 2005, Typical medullary breast carcinomas have a basal/myoepithelial phenotype, J Pathol, 207, 260, 10.1002/path.1845
Moreira, 2005, Down-regulation of the tumor suppressor protein 14-3-3sigma is a sporadic event in cancer of the breast, Mol Cell Proteomics, 4, 555, 10.1074/mcp.M400205-MCP200
Simon, 2001, Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer, J Natl Cancer Inst, 93, 1141, 10.1093/jnci/93.15.1141
Van den Eynden, 2004, Validation of a tissue microarray to study differential protein expression in inflammatory and non-inflammatory breast cancer, Breast Cancer Res Treat, 85, 13, 10.1023/B:BREA.0000021028.33926.a8
Charafe-Jauffret, 2004, Immunophenotypic analysis of inflammatory breast cancers: identification of an ’inflammatory signature’, J Pathol, 202, 265, 10.1002/path.1515
Sorlie, 2001, Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications, Proc Natl Acad Sci U S A, 98, 10869, 10.1073/pnas.191367098
Korsching, 2002, Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis, Lab Invest, 82, 1525, 10.1097/01.LAB.0000038508.86221.B3
Callagy, 2003, Molecular classification of breast carcinomas using tissue microarrays, Diagn Mol Pathol, 12, 27, 10.1097/00019606-200303000-00004
Zhang, 2003, Tissue microarray study for classification of breast tumors, Life Sci, 73, 3189, 10.1016/j.lfs.2003.05.006
Jacquemier, 2005, Protein expression profiling identifies subclasses of breast cancer and predicts prognosis, Cancer Res, 65, 767, 10.1158/0008-5472.767.65.3
Abd El-Rehim, 2005, High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses, Int J Cancer, 116, 340, 10.1002/ijc.21004
Makretsov, 2004, Hierarchical clustering analysis of tissue microarray immunostaining data identifies prognostically significant groups of breast carcinoma, Clin Cancer Res, 10, 6143, 10.1158/1078-0432.CCR-04-0429
Nielsen, 2004, Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma, Clin Cancer Res, 10, 5367, 10.1158/1078-0432.CCR-04-0220
Cheang, 2008, Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype, Clin Cancer Res, 14, 1368, 10.1158/1078-0432.CCR-07-1658
Choi, 2009, Tissue microarray-based study of patients with lymph node-negative breast cancer shows that HER2/neu overexpression is an important predictive marker of poor prognosis, Ann Oncol, 20, 1337, 10.1093/annonc/mdp003
Ristimaki, 2002, Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer, Cancer Res, 62, 632
Poremba, 2002, Telomerase as a prognostic marker in breast cancer: high-throughput tissue microarray analysis of hTERT and hTR, J Pathol, 198, 181, 10.1002/path.1191
Spizzo, 2004, High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer, Breast Cancer Res Treat, 86, 207, 10.1023/B:BREA.0000036787.59816.01
Ginestier, 2003, Loss of FHIT protein expression is a marker of adverse evolution in good prognosis localized breast cancer, Int J Cancer, 107, 854, 10.1002/ijc.11462
Nevalainen, 2004, Signal transducer and activator of transcription-5 activation and breast cancer prognosis, J Clin Oncol, 22, 2053, 10.1200/JCO.2004.11.046
Callagy, 2006, Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index, Clin Cancer Res, 12, 2468, 10.1158/1078-0432.CCR-05-2719
Pusztai, 2009, Evaluation of microtubule-associated protein-Tau expression as a prognostic and predictive marker in the NSABP-B 28 randomized clinical trial, J Clin Oncol, 27, 4287, 10.1200/JCO.2008.21.6887
Mehra, 2005, Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis, Cancer Res, 65, 11259, 10.1158/0008-5472.CAN-05-2495
Badve, 2007, FOXA1 expression in breast cancer--correlation with luminal subtype A and survival, Clin Cancer Res, 13, 4415, 10.1158/1078-0432.CCR-07-0122
Thorat, 2008, Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis, J Clin Pathol, 61, 327, 10.1136/jcp.2007.052431
Moyano, 2006, AlphaB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer, J Clin Invest, 116, 261, 10.1172/JCI25888
Stein, 2005, Annexin A8 is up-regulated during mouse mammary gland involution and predicts poor survival in breast cancer, Clin Cancer Res, 11, 6872, 10.1158/1078-0432.CCR-05-0547
Goncalves, 2008, Protein profiling of human breast tumor cells identifies novel biomarkers associated with molecular subtypes, Mol Cell Proteomics, 7, 1420, 10.1074/mcp.M700487-MCP200
Linke, 2006, A multimarker model to predict outcome in tamoxifen-treated breast cancer patients, Clin Cancer Res, 12, 1175, 10.1158/1078-0432.CCR-05-1562
Dolled-Filhart, 2006, Classification of breast cancer using genetic algorithms and tissue microarrays, Clin Cancer Res, 12, 6459, 10.1158/1078-0432.CCR-06-1383
Voduc, 2008, The combination of high cyclin E and Skp2 expression in breast cancer is associated with a poor prognosis and the basal phenotype, Hum Pathol, 39, 1431, 10.1016/j.humpath.2008.03.004
Haab, 2005, Antibody Arrays in Cancer Research, Mol Cell Proteomics %R 10.1074/mcp.M500010-MCP200, 4, 377, 10.1074/mcp.M500010-MCP200
Hudelist, 2004, Use of high-throughput protein array for profiling of differentially expressed proteins in normal and malignant breast tissue, Breast Cancer Res Treat, 86, 281, 10.1023/B:BREA.0000036901.16346.83
Celis, 2005, Identification of Extracellular and Intracellular Signaling Components of the Mammary Adipose Tissue and Its Interstitial Fluid in High Risk Breast Cancer Patients: Toward Dissecting The Molecular Circuitry of Epithelial-Adipocyte Stromal Cell Interactions, Mol Cell Proteomics %R 10.1074/mcp.M500030-MCP200, 4, 492, 10.1074/mcp.M500030-MCP200
Woodbury, 2002, Elevated HGF levels in sera from breast cancer patients detected using a protein microarray ELISA, J Proteome Res, 1, 233, 10.1021/pr025506q
Lin, 2004, Identification of interleukin-8 as estrogen receptor-regulated factor involved in breast cancer invasion and angiogenesis by protein arrays, Int J Cancer, 109, 507, 10.1002/ijc.11724
Vazquez-Martin, 2007, Protein array technology to detect HER2 (erbB-2)-induced ’cytokine signature’ in breast cancer, Eur J Cancer, 43, 1117, 10.1016/j.ejca.2007.01.037
Nielsen, 2003, Profiling receptor tyrosine kinase activation by using Ab microarrays, Proc Natl Acad Sci U S A, 100, 9330, 10.1073/pnas.1633513100
Keyes, 2002, An In Vitro Tumor Model: Analysis of Angiogenic Factor Expression after Chemotherapy, Cancer Res, 62, 5597
Dehqanzada, 2007, Assessing serum cytokine profiles in breast cancer patients receiving a HER2/neu vaccine using Luminex technology, Oncol Rep, 17, 687
Liotta, 2003, Protein microarrays: meeting analytical challenges for clinical applications, Cancer Cell, 3, 317, 10.1016/S1535-6108(03)00086-2
Rapkiewicz, 2007, The needle in the haystack: application of breast fine-needle aspirate samples to quantitative protein microarray technology, Cancer, 111, 173, 10.1002/cncr.22686
Wilm, 1996, Femtomole sequencing of proteins from polyacrylamide gels by nano-electrospray mass spectrometry, Nature, 379, 466, 10.1038/379466a0
Nesvizhskii, 2007, Protein identification by tandem mass spectrometry and sequence database searching, Methods Mol Biol, 367, 87
O’Farrell, 1975, High resolution two-dimensional electrophoresis of proteins, J Biol Chem, 250, 4007, 10.1016/S0021-9258(19)41496-8
Bergman, 2000, Identification of gel-separated tumor marker proteins by mass spectrometry, Electrophoresis, 21, 679, 10.1002/(SICI)1522-2683(20000201)21:3<679::AID-ELPS679>3.0.CO;2-A
Bini, 1997, Protein expression profiles in human breast ductal carcinoma and histologically normal tissue, Electrophoresis, 18, 2832, 10.1002/elps.1150181519
Franzen, 1996, Assessment of homogeneity in polypeptide expression in breast carcinomas shows widely variable expression in highly malignant tumors, Int J Cancer, 69, 408, 10.1002/(SICI)1097-0215(19961021)69:5<408::AID-IJC10>3.0.CO;2-Z
Franzen, 1996, Analysis of polypeptide expression in benign and malignant human breast lesions: down-regulation of cytokeratins, Br J Cancer, 74, 1632, 10.1038/bjc.1996.600
Hondermarck, 2001, Proteomics of breast cancer for marker discovery and signal pathway profiling, Proteomics, 1, 1216, 10.1002/1615-9861(200110)1:10<1216::AID-PROT1216>3.0.CO;2-P
Somiari, 2005, Proteomics of breast carcinoma, J Chromatogr B Analyt Technol Biomed Life Sci, 815, 215, 10.1016/j.jchromb.2004.11.012
Vercoutter-Edouart, 2001, Proteomic analysis reveals that 14-3-3sigma is down-regulated in human breast cancer cells, Cancer Res, 61, 76
Wulfkuhle, 2001, New approaches to proteomic analysis of breast cancer, Proteomics, 1, 1205, 10.1002/1615-9861(200110)1:10<1205::AID-PROT1205>3.0.CO;2-X
Wulfkuhle, 2002, Proteomics of human breast ductal carcinoma in situ, Cancer Res, 62, 6740
Jung, 2007, Galectin-1 expression in cancer-associated stromal cells correlates tumor invasiveness and tumor progression in breast cancer, Int J Cancer, 120, 2331, 10.1002/ijc.22434
Alexander, 2004, Proteomic Analysis to Identify Breast Cancer Biomarkers in Nipple Aspirate Fluid, Clin Cancer Res %R 10.1158/1078-0432.CCR-04-1002, 10, 7500
Goufman, 2006, Two-dimensional electrophoretic proteome study of serum thermostable fraction from patients with various tumor conditions, Biochemistry (Mosc), 71, 354, 10.1134/S000629790604002X
Bloom, 2004, Multi-platform, multi-site, microarray-based human tumor classification, Am J Pathol, 164, 9, 10.1016/S0002-9440(10)63090-8
Niméus, 2007, Proteomic analysis identifies candidate proteins associated with distant recurrences in breast cancer after adjuvant chemotherapy, J Pharm Biomed Anal, 43, 1086, 10.1016/j.jpba.2006.09.019
Unlu, 1997, Difference gel electrophoresis: a single method for detecting changes in protein extracts, Electrophoresis, 18, 2071, 10.1002/elps.1150181133
Traub, 2006, Peptidomic analysis of breast cancer reveals a putative surrogate marker for estrogen receptor-negative carcinomas, Lab Invest, 86, 246, 10.1038/labinvest.3700385
Washburn, 2001, Large-scale analysis of the yeast proteome by multidimensional protein identification technology, Nat Biotechnol, 19, 242, 10.1038/85686
Gygi, 1999, Quantitative analysis of complex protein mixtures using isotope-coded affinity tags, Nat Biotechnol, 17, 994, 10.1038/13690
Pawlik, 2006, Proteomic analysis of nipple aspirate fluid from women with early-stage breast cancer using isotope-coded affinity tags and tandem mass spectrometry reveals differential expression of vitamin D binding protein, BMC Cancer, 6, 68, 10.1186/1471-2407-6-68
Leth-Larsen, 2009, Metastasis-related plasma membrane proteins of human breast cancer cells identified by comparative quantitative mass spectrometry, Mol Cell Proteomics, 8, 1436, 10.1074/mcp.M800061-MCP200
Garbis, 2008, Search for potential markers for prostate cancer diagnosis, prognosis and treatment in clinical tissue specimens using amine-specific isobaric tagging (iTRAQ) with two-dimensional liquid chromatography and tandem mass spectrometry, J Proteome Res., 7, 3146, 10.1021/pr800060r
Chen, 2007, Differential expression of novel tyrosine kinase substrates during breast cancer development, Mol Cell Proteomics, 6, 2072, 10.1074/mcp.M700395-MCP200
Bouchal, 2009, Biomarker discovery in low-grade breast cancer using isobaric stable isotope tags and two-dimensional liquid chromatography-tandem mass spectrometry (iTRAQ-2DLC-MS/MS) based quantitative proteomic analysis, J Proteome Res., 8, 362, 10.1021/pr800622b
Brancia, 2006, Recent developments in ion-trap mass spectrometry and related technologies, Expert Rev Proteomics, 3, 143, 10.1586/14789450.3.1.143
Payne, 2005, Tandem mass spectrometry in quadrupole ion trap and ion cyclotron resonance mass spectrometers, Methods Enzymol, 402, 109, 10.1016/S0076-6879(05)02004-5
Solassol, 2005, Bull Cancer, 92, 763
Issaq, 2002, The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification, Biochem Biophys Res Commun, 292, 587, 10.1006/bbrc.2002.6678
Clarke, 2005, SELDI-TOF-MS proteomics of breast cancer, Clin Chem Lab Med, 43, 1314, 10.1515/CCLM.2005.225
Koopmann, 2004, Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry, Clin Cancer Res, 10, 860, 10.1158/1078-0432.CCR-1167-3
Kozak, 2003, Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: Potential use in diagnosis and prognosis, PNAS, 100, 12343, 10.1073/pnas.2033602100
Petricoin, 2002, Use of proteomic patterns in serum to identify ovarian cancer, Lancet, 359, 572, 10.1016/S0140-6736(02)07746-2
Petricoin, 2002, Serum Proteomic Patterns for Detection of Prostate Cancer, J Natl Cancer Inst, 94, 1576, 10.1093/jnci/94.20.1576
Won, 2003, Pattern analysis of serum proteome distinguishes renal cell carcinoma from other urologic diseases and healthy persons, Proteomics, 3, 2310, 10.1002/pmic.200300590
Zhang, 2004, Three Biomarkers Identified from Serum Proteomic Analysis for the Detection of Early Stage Ovarian Cancer, Cancer Res, 64, 5882, 10.1158/0008-5472.CAN-04-0746
Diamandis, 2004, Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems, J Natl Cancer Inst, 96, 353, 10.1093/jnci/djh056
Hu, 2005, SELDI-TOF-MS: the proteomics and bioinformatics approaches in the diagnosis of breast cancer, Breast, 14, 250, 10.1016/j.breast.2005.01.008
Li, 2002, Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer, Clin Chem, 48, 1204, 10.1093/clinchem/48.8.1296
Vlahou, 2003, A novel approach toward development of a rapid blood test for breast cancer, Clin Breast Cancer, 4, 203, 10.1016/S1526-8209(11)70627-9
Belluco, 2007, Serum proteomic analysis identifies a highly sensitive and specific discriminatory pattern in stage 1 breast cancer, Ann Surg Oncol, 14, 2470, 10.1245/s10434-007-9354-3
Li, 2005, Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry, Clin Chem, 51, 2229, 10.1373/clinchem.2005.052878
Becker, 2004, Surfaced-enhanced laser desorption/ionization time-of-flight (SELDI-TOF) differentiation of serum protein profiles of BRCA-1 and sporadic breast cancer, Ann Surg Oncol, 11, 907, 10.1245/ASO.2004.03.557
Shi, 2006, Declining Plasma Fibrinogen Alpha Fragment Identifies HER2-Positive Breast Cancer Patients and Reverts to Normal Levels after Surgery, J Proteome Res, 5, 2947, 10.1021/pr060099u
Paweletz, 2001, Proteomic patterns of nipple aspirate fluids obtained by SELDI-TOF: potential for new biomarkers to aid in the diagnosis of breast cancer, Dis Markers, 17, 301, 10.1155/2001/674959
Pawlik, 2005, Significant differences in nipple aspirate fluid protein expression between healthy women and those with breast cancer demonstrated by time-of-flight mass spectrometry, Breast Cancer Res Treat, 89, 147, 10.1007/s10549-004-1710-4
Noble, 2007, A comparative proteinomic analysis of nipple aspiration fluid from healthy women and women with breast cancer, Eur J Cancer, 43, 2315, 10.1016/j.ejca.2007.08.009
Kuerer, 2004, Association between ductal fluid proteomic expression profiles and the presence of lymph node metastases in women with breast cancer, Surgery, 136, 1061, 10.1016/j.surg.2004.04.011
Goncalves, 2006, Postoperative serum proteomic profiles may predict metastatic relapse in high-risk primary breast cancer patients receiving adjuvant chemotherapy, Oncogene, 25, 981, 10.1038/sj.onc.1209131
Ricolleau, 2006, Surface-enhanced laser desorption/ionization time of flight mass spectrometry protein profiling identifies ubiquitin and ferritin light chain as prognostic biomarkers in node-negative breast cancer tumors, Proteomics, 6, 1963, 10.1002/pmic.200500283
Nakagawa, 2006, Proteomic profiling of primary breast cancer predicts axillary lymph node metastasis, Cancer Res, 66, 11825, 10.1158/0008-5472.CAN-06-2337
Pusztai, 2004, Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma, Cancer, 100, 1814, 10.1002/cncr.20203
Heike, 2005, Identification of serum proteins related to adverse effects induced by docetaxel infusion from protein expression profiles of serum using SELDI ProteinChip system, Anticancer Res, 25, 1103
Goncalves, 2007, Serum proteomic prediction of progression-free survival in HER2-negative metastatic breast cancer patients receiving docetaxel as first-line treatment, J Clin Oncol, 25, 1010, 10.1200/jco.2007.25.18_suppl.1010
Shin, 2007, Serum biomarkers to differentiate benign and malignant mammographic lesions, J Am Coll Surg, 204, 1065, 10.1016/j.jamcollsurg.2007.01.036
Villanueva, 2006, Serum peptidome patterns that distinguish metastatic thyroid carcinoma from cancer-free controls are unbiased by gender and age, Mol Cell Proteomics, 5, 1840, 10.1074/mcp.M600229-MCP200
Schwartz, 2004, Protein profiling in brain tumors using mass spectrometry: feasibility of a new technique for the analysis of protein expression, Clin Cancer Res, 10, 981, 10.1158/1078-0432.CCR-0927-3
Schwartz, 2005, Proteomic-based prognosis of brain tumor patients using direct-tissue matrix-assisted laser desorption ionization mass spectrometry, Cancer Res, 65, 7674, 10.1158/0008-5472.CAN-04-3016
Yanagisawa, 2003, Proteomic patterns of tumour subsets in non-small-cell lung cancer, Lancet, 362, 433, 10.1016/S0140-6736(03)14068-8
Cornett, 2006, A novel histology-directed strategy for MALDI-MS tissue profiling that improves throughput and cellular specificity in human breast cancer, Mol Cell Proteomics, 5, 1975, 10.1074/mcp.M600119-MCP200